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Abstract
● AIM: To evaluate safety, efficacy, and patient adherence 
of intracameral lidocaine as supplement of classic topical 
anesthetic drops in cataract surgery.
● METHODS: A prospective and controlled trial including a 
large cohort of 1650 individuals suffering with bilateral cataract 
not complicated, in program by phacoemulsification 
surgery, were randomly assigned to 2 different groups 
for the type of anesthesia received, 0.4% oxybuprocaine 
hydrochloride (INN) drops, and INN drops associated to 
intracameral 1% lidocaine hydrochloride monohydrate. At 
the end of surgery, tables were assigned to each patient 
indicating the degree of pain (0-3) felt during the operation.
● RESULTS: Thirty-two percent of patients in group 1 
declared to have not felt any pain against the 77% of patients 
in group 2. Fifty-nine percent of patients in group 1 complained 
about only a slight discomfort against 20% of group 2 
patients. Only a small percentage of patients in group 1 (5%) 
admitted severe pain, while no patient in group 2 admitted 
severe pain. Four patients of group 2 reported an episode 
of transient amaurosis, lasting several hours after surgery.
● CONCLUSION: Intracameral administration of lidocaine 
is a simple and secure method able to increase the 
analgesia during the cataract surgery, eliminating the 
discomfort and increasing also the cooperation of the 
patients during the steps of manipulation.
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INTRODUCTION
C ataract is the leading cause of preventable visual impairment causing an estimated 43% of all cases of 
blindness worldwide. Phacoemulsification with intraocular lens 
(IOL) implantation has become the primary surgery to remove 
cataracts[1-2]. Recent ophthalmic methods of local anesthesia 
have been developed to improve preference, comfort, and 
adherence of treated patients. Some complications associated 
with retrobulbar or peribulbar anesthesia can be avoided with 
administration of topical anesthesia in drops. Furthermore, 
intracameral (IC) anesthesia involves the injection of 
anesthetics directly into the anterior chamber of the eye at the 
start of the surgery[1-2]. In fact, lidocaine seems to be a simple 
and safe method for increasing the topical anesthesia obtained 
by the use of drops of 0.4% oxybuprocaine hydrochloride 
(INN) before phacoemulsification of the cataract[3].
INN, is an ester-type local anesthetic, also known as benoxinate 
hydrochloride, which is used especially in ophthalmology and 
otolaryngology. INN, when used excessively in the eye and 
on mucous membranes, can cause irritation, hypersensitivity, 
anaphylaxis, and irreversible corneal damage, like any other 
topical anesthetics[1-3].
Lidocaine hydrochloride, also known as xylocaine and 
lignocaine, is a medication used to cause reversible absence 
of pain sensation in a specific area, for nerve blocks, and 
to treat ventricular tachycardia[4-5]. Its acting typically starts 
within a few minutes and lasts up to several hours. Side effects 
with intravenous use include sleepiness, muscle twitching, 
confusion, changes in vision, numbness, tingling, vomiting, 
low blood pressure, and irregular heart rate[4-5].
Lidocaine was discovered in 1946 and it is on the list of 
medications proposed by the World Health Organization to meet 
the most important needs in a basic healthcare system; it can be 
administered by intravenous, subcutaneous, topical, and oral via[6].
More, IC anesthesia is especially useful in the case of handling 
of tissues, decreasing the discomfort of patient and increasing, 
therefore, also its cooperation during the surgery[6-11]. 
Accordingly, the objective of our study was to evaluate patient 
preference, satisfaction, and acceptability during the cataract 
surgery, when the patients were treated with supplementation 
of IC injection of lidocaine. Furthermore, we wanted to 
determine whether the administration of lidocaine could 
optimize or not the adherence and clinical outcomes.
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SUBJECTS AND METHODS
From January 2014 to December 2016 the eyes of 1650 
patients suffering from bilateral cataract and in program to be 
subjected to surgical intervention, were enrolled in our study 
from the Ophthalmologic Ambulatory of the Santa Maria 
Goretti Civil Hospital, Latina, Italy. The study protocol was 
approved by the Ethics Committees and, in accordance with 
Helsinki Declaration, written consent was obtained from all 
the subjects.
The inclusion criteria for all patients enrolled were: participants of 
Caucasian race classified as well-nourished with measurable 
visual acuity, normal intraocular pressure (IOP), not 
complicated bilateral cataract, macular areas and retinal nerve 
fibre layers with normal values by spectral domain-optical 
coherence tomography.
The exclusion criteria from the study were: patients with 
hypermature cataract, signs of exudative or atrophic age-
related macular degeneration, or other ocular disorders 
associated, such as macular pucker, neovascular membranes, 
chorioretinal disease, glaucoma, optic neuritis, ocular trauma, 
etc. Individuals affected from systemic diseases, like: mutiple 
sclerosis, Parkinson disease, dementia, diabetes mellitus, 
vasculitis, renal and hepatic diseases, cancer, etc. Patients 
with problems that would make it more difficult to fixate 
the microscope light, like: movement disorders, nystagmus, 
hearing problems, high degree of anxiety, etc. 
The individuals were randomly divided into 2 groups according 
to the type of anesthesia to which the eye being examined 
was subjected. The first eye of 1650 patients with less visual 
acuity was enrolled in the first study group. These eyes were 
anesthetized using 4 drops of INN (sold by Novartis Pharma 
SpA Schweizerhalle AG-Rothausweg, CH-4133 Pratteln 
Switzerland under the brand names of Novesin). The second 
group was composed of the contralateral eye of the same 
patients who underwent surgery 1 or 2mo before. These eyes 
were anesthetized using 4 drops of INN and a supplementation 
of IC preservative-free 1% lidocaine hydrochloride monohydrate 
(sold by Fisiopharma S.r.l. Palomonte, Salerno-Italy under 
the brand names of Lidocaina Cloridrato Fisiopharma) 
introduced in the anterior chamber immediately after the 
corneal incisions and before the capsulorhexis. During the 
surgery a clear corneal incision was made with a keratome. 
Immediately prior to capsulorrhexis the contents of the 
syringe (0.2 mL) was injected by irrigation into the anterior 
chamber only in the patients of the group 2. The solution of 
1% lidocaine hydrochloride was then left in the eye for two 
minutes. After this, viscoelastic was injected to fill the anterior 
chamber and the surgeon proceeded with the remainder of the 
surgery: capsulorrhexis, hydrodissection, phacoemulsification, 
aspiration of cortical material and insertion of an IOL. The 
wounds were not sutured at the end of the surgery.
Immediately after the surgery, each patient was asked to fill a 
numeric table descriptive from 0 to 3, which would indicate 
the pain experienced during surgery suffered. Zero indicated 
complete absence of pain, 1-mild discomfort, 2-pain tolerable, 
and 3-pain very strong. The patient was asked, “Did you 
experience any pain during the surgery? Would you make a 
mark on the line to show us how much pain you experienced?”
From 2014 to date, the following steps were taken. First the 
patients were followed up weekly and then every two months. This 
was to ensure that the lidocaine did not cause any toxic effect, 
especially on corneal epithelium, by an ocular examination 
consisting of: measurement of unaided and best corrected 
visual acuity, evaluation of the anterior segment using the 
slit-lamp biomicroscopy, IOP check using the Goldmann’s 
applanation tonometer, and eye fundus examination.
Statistical Analysis  Gender distribution was compared by 
Chi-square test (χ2). The scores corresponding to pain assessment 
were compared by means of the Chi-square test. The variation 
in the percentage of patients who reported not to feel pain 
between the immediate postoperative period and six hours 
after surgery was assessed by the Fisher exact test. Statistical 
analysis was performed using the STATA 14.0 (Collage Station, 
Texas, USA), and the null hypothesis was rejected if P<0.05.
RESULTS
A cohort of 1650 patients suffering from bilateral cataract to 
be subjected to surgical intervention was enrolled in our study. 
Once the study started, no patient was excluded and 3300 eyes 
were operated. The mean age of the 1650 individuals included 
was 71.2±5.4y (range 59-85); 42% were male and 58% were female. 
All subjects had day-case surgery. None of our patients had 
intraoperative complications related to the administration of IC 
lidocaine (ICL), that would interfere with the continuation of 
the intervention and no one needed peribulbar or retrobulbar 
anesthesia or sedation with intravenous benzodiazepines. The 
pain scores reported by patients after surgery are shown in the 
Table 1 and Figure 1. Thirty-two percent of patients in group 
1 reported no pain (score=0) against the 77% of the group 2. 
Fifty-nine percent of patients in group 1 complained of mild 
discomfort (score=1) against the 20% of the group 2. Only 4% 
Table 1 Pain scores reported by patients after surgery; percentage 
breakdown of the pain level intraoperative of 3300 eyes in 1650 
patients 






SD: Standard deviation; 0: No pain; 1: Low pain; 2: Mild pain; 3: 
Severe pain. Statistically significant with P<0.05.
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of the patients in group 1 complained of pain (score=2) and 
5% of severe pain (score=3) during surgery, while 3% of the 
patients belonging to the second group claimed to feel pain 
and none of severe pain during the same procedures (Table 1). 
At time 6h after surgery, 98.1% of the participants reported no 
pain, and 1.9% reported mild discomfort (score: 0/1). During 
the months of follow up, the patients showed no evidence of 
corneal damage related to IC injection of lidocaine. 
Surgical complications included only one case of small 
posterior capsule rupture and vitreous loss in a patient 
belonging to the group 2. However, this patient was able to 
tolerate a mechanical anterior vitrectomy without supplemental 
retrobulbar anesthesia. Right after a foldable IOL was 
implanted into the capsular bag in the eye without difficulty.
Adverse events after surgery occurred in four of the patients 
treated with lidocaine who developed transient amaurosis. 
Two of them were highly myopic. In a word, the posterior 
capsule was not intact, while the fourth subject had undergone 
a vitrectomy 25y earlier. All patients in the span of a few hours 
regained their sight without other side effects or permanent deficit. 
DISCUSSION
The objective of our research consisted of evaluating the 
compliance and adherence of the patients during cataract 
surgery using combined IC injection of lidocaine as 
supplement to classic topical anesthesia for the treatment 
of ocular pain in cataract surgery. Moreover, we wanted to 
determine whether or not the administration of lidocaine could 
optimize the safety and efficacy of the clinical outcomes in a 
large group of monitored eyes. 
It is also clear that the percentage of patients experiencing pain 
decreases considerably from the first to the second group, with 
the addition of ICL, the perception of pain disappears or at least 
it is widely reduced. In fact, 59% of the patients of the group 
1 declared discomfort during several times of the surgery: 
manipulation of iris, sudden distension of the anterior chamber 
by irrigating fluid, after introduction of the phacoemulsification 
tip, or hydrodissection, or rotation of the nucleus. The most 
afflicting pain happened during the use of spatula to reposition 
a prolapsed iris. A smaller proportion of patients in group 2 
(20%) reported ocular discomfort during such manipulations, 
although most described a sensation of ocular soreness when 
the lidocaine was injected in anterior chamber. Generally, 
such discomfort lasted for only few seconds and some words 
of comfort and encouragement were sufficient to ward off the 
patient’s anxiety. Despite the fact that majority of the patients 
did not suffer intraoperative uneasiness, the difference in mean 
pain scores for the two groups was statistically significant. 
Similar findings have been recorded by other authors[2,11].
So, while some researchers declare that ICL seems to be safe 
for cornea, anterior chamber, retina, and no relevant systemic 
levels of lidocaine have been reported[11-13]. We reported 4 
events of amaurosis fugax similar to other authors[7-8,14-15]. In 
addition, Macky et al[16] have carried out some investigation 
on the toxicity of a solution that combines sodium hyaluronate 
1.5% with lidocaine (0.5%, 1.0%, and 1.65%) to intraocular 
tissues during phacoemulsification in both eyes of 29 rabbits. 
The results showed no evidence of an inflammatory reaction, 
cell necrosis, or cell degeneration was observed in the 
histological sections in intraocular structures such as the iris, 
lens capsular bag, ciliary body and retina. The researchers have 
concluded that the use of 3 lidocaine concentrations during 
phacoemulsification of the lens appeared to be safe, with no 
tissue histopathological abnormalities observed in multiple 
sections of eyes from iris, ciliary body, lens, and retina[16]. 
We know that the lidocaine alters the signal conduction 
in sensory neurons as well as in muscle cells by blocking 
fast sodium channels and increasing the depolarization 
threshold[17-18]. The adverse drug reactions are rare when 
lidocaine is used as a local anesthetic and is administered 
correctly. In the eyes it can cause: local burning, conjunctival 
hyperemia, corneal ulceration, diplopia, and visual changes. 
While, cardiovascular adverse effects can be: hypotension, 
bradycardia, arrhythmias, venous insufficiency, increased 
defibrillator threshold, edema, and cardiac arrest[17-19]. However, 
these were not seen in our study intra- and postoperatively.
On the other hand, in amaurosis fugax, also known as transitory 
monocular blindness, the sight in one eye is temporarily lost. 
To the best of our knowledge, we have found in the literature a 
few similar events of transient amaurosis after cataract surgery 
with IC anesthetic of lidocaine. These adverse events are, 
perhaps, linked to the large number of patients we have treated 
and carefully monitored to assert the safety of the lidocaine. 
Accidentally, also other authors reported cases of transient 
visual loss after use of ICL with or without posterior capsule 
rupture[14-15,20]. Although in a Lincoff et al[7] research only one 
subject developed a permanent visual field defect and the other 
patients showed improvement in retinal function up to 16h. 
Figure 1 Comparison of the percentage of pain levels in the two 
study groups (3300 eyes of 1650 patients).
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Researchers stated that lidocaine temporarily paralyzed the 
pupil in mydriasis and temporarily extinguished the b-wave of 
the electroretinogram for decrease in amplitude and increase 
in implicit time. Nevertheless, electroretinogram responses 
recovered within 24h[7,14-15]. Eshraghi et al[20] concluded that to 
reduce retinal toxicity risks, ICL should not be repeated during 
the surgery.
Probably, the temporary visual loss in our patients could be 
caused by action of topical anesthetic agent on the retinal 
vessels, we also remember vasodilatation effect of the 
lidocaine[17-18], through a retinal ischemia or directly on the 
retinal nerve fiber layer, in turn, because of lack of barrier 
effect of posterior capsule, zonules, and vitreous humor. However, 
the retina and optic nerve head of our 4 patients appeared 
normal. Therefore, the retina could be resistant to the toxic 
effects of ICL only to lower concentrations of the anesthetic. 
In a recent study, it was confirmed in vitro the toxic effect of 
lidocaine on ganglion cells by molecular degenerative damage 
and also observed that lidocaine 0.25% decreases cell viability 
and causes DNA degradation in murine fibroblasts 3T6[8].
In conclusion, based on the results obtained, we believe 
that the combined topical IC approach will probably 
become the standard ophthalmic anesthetic technique in 
phacoemulsification for the majority of our patients undergoing 
cataract surgery. However, it is very important to note the need 
for the moderate use of the anesthetic agent’s concentration 
and quantity, particularly in case of rupture of capsule bag.
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